Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Liver Fibrosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    379 result(s) found for: Liver Fibrosis. Displaying page 1 of 19.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-006023-33 Sponsor Protocol Number: SIMFIB Start Date*: 2021-10-26
    Sponsor Name:Institut d’Investigacions Biomèdiques August Pi i Sunyer
    Full Title: Efficacy of simvastatin reducing liver fibrosis in patients with advanced fibrosis due to alcohol: a randomized, double-blind, placebo-controlled clinical trial.
    Medical condition: reduction of liver fibrosis in patients with advanced fibrosis due to alcohol
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10001627 Alcoholic liver disease PT
    20.0 10019805 - Hepatobiliary disorders 10019668 Hepatic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002295-10 Sponsor Protocol Number: 58/2008/U/Sper Start Date*: 2008-10-14
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Role of immunosuppression with steroids in the outcome of fibrosis due to recurrent hepatitis C virus (HCV) infection after liver transplantation
    Medical condition: fibrosis due to recurrent hepatitis C virus (HCV) infection after liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016648 Fibrosis liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004882-26 Sponsor Protocol Number: ND-L02-s0201-002 Start Date*: 2015-03-25
    Sponsor Name:Nitto Denko Corporation
    Full Title: A Phase 1b/2, Open Label, Randomized, Repeat Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Biological Activity and Pharmacokinetics of ND L02 s0201 Injection, a Vitamin A-couple...
    Medical condition: Moderate to extensive progressive hepatic fibrosis (METAVIR F3-4)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10019805 - Hepatobiliary disorders 10019668 Hepatic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-001221-28 Sponsor Protocol Number: COLO400A2426 Start Date*: 2005-11-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, open label study to compare the development of liver fibrosis at 12 months after transplantation for hepatitis C cirrhosis in patients receiving either Neoral or tacrolim...
    Medical condition: Development of liver fibrosis after transplantation for hepatitis C cirrhosis.
    Disease: Version SOC Term Classification Code Term Level
    M15 10016648 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) IT (Completed) BE (Completed) PT (Completed) DE (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004594-44 Sponsor Protocol Number: NN9931-4553 Start Date*: 2021-06-28
    Sponsor Name:Novo Nordisk A/S
    Full Title: The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis
    Medical condition: Non-alcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DE (Ongoing) IE (Ongoing) CZ (Trial now transitioned) GR (Ongoing) DK (Trial now transitioned) FR (Ongoing) NL (Ongoing) SK (Trial now transitioned) PT (Trial now transitioned) BE (Ongoing) BG (Ongoing) PL (Ongoing) IT (Ongoing) HR (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010808-28 Sponsor Protocol Number: HBV BID Start Date*: 2010-02-10
    Sponsor Name:Kings College Hospital NHS Foundation Trust [...]
    1. Kings College Hospital NHS Foundation Trust
    2. King's College London
    Full Title: Role of Non-invasive test in detecting fibrosis in chronic hepatitis B patients
    Medical condition: Level of fibrosis in patients with chronic Hepatitis B(HBV).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10016648 Fibrosis Liver LLT
    12.0 10008910 Chronic hepatitis B LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004775-39 Sponsor Protocol Number: C2541013 Start Date*: 2020-08-21
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINI...
    Medical condition: BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGE 2 OR 3
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    20.0 10019805 - Hepatobiliary disorders 10019668 Hepatic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) SK (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002518-42 Sponsor Protocol Number: FIBRO-COVID Start Date*: 2020-07-20
    Sponsor Name:IDIBELL
    Full Title: A RANDOMIZED PHASE-II CLINICAL TRIAL TO EVALUATE THE EFFECT OF PIRFENIDONE COMPARED WITH PLACEBO IN PULMONARY FIBROSIS POST-COVID 19:
    Medical condition: Pulmonary fibrosis induced by SARS-COV2 virus (post-COVID19 pulmonary sequelae)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037383 Pulmonary fibrosis PT
    23.0 100000004862 10084510 Coronavirus infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004986-38 Sponsor Protocol Number: 337HNAS20011 Start Date*: 2022-01-04
    Sponsor Name:Inventiva S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatiti...
    Medical condition: Non-alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Ongoing) ES (Ongoing) AT (Completed) HU (Ongoing) BG (Ongoing) IT (Ongoing) NL (Ongoing) PL (Ongoing) BE (Ongoing) PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002560-16 Sponsor Protocol Number: 747-303 Start Date*: 2015-12-10
    Sponsor Name:Intercept Pharmaceuticals Inc.
    Full Title: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
    Medical condition: Nonalcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Completed) SE (Completed) BE (Completed) DK (Completed) ES (Prematurely Ended) FI (Completed) PT (Prematurely Ended) HU (Completed) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-002937-11 Sponsor Protocol Number: ANRS HC 15 Start Date*: 2008-01-23
    Sponsor Name:ANRS (Agence Nationale de Recherche sur le SIDA et les hépatites virales)
    Full Title: Etude randomisée, en double insu et multicentrique de l'association Interferon pégylé alpha 2b-Ribavirine versus l'association Interferon pégylé alpha 2b-placebo dans le traitement au long cours (3...
    Medical condition: Hepatic fibrosis in non responders patients with chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019668 Hepatic fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-003164-21 Sponsor Protocol Number: 652-2-203 Start Date*: 2015-01-05
    Sponsor Name:Tobira Therapeutics, Inc., a subsidiary of Allergan plc
    Full Title: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis
    Medical condition: Nonalcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003932-22 Sponsor Protocol Number: IM025-017 Start Date*: 2022-10-04
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic ...
    Medical condition: Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10019669 Hepatic fibrosis and cirrhosis HLT
    20.1 100000004871 10064844 Compensated cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DE (Completed) IT (Ongoing) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005484-53 Sponsor Protocol Number: D5671C00006 Start Date*: 2022-06-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIb/III Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis with Fibrosis
    Medical condition: Non-cirrhotic non-alcoholic steatohepatitis with fibrosis
    Disease: Version SOC Term Classification Code Term Level
    24.1 100000004871 10086370 NASH with fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GR (Ongoing) AT (Completed) ES (Ongoing) IT (Ongoing) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004566-26 Sponsor Protocol Number: 3152-301-002 Start Date*: 2017-06-19
    Sponsor Name:Tobira Therapeutics Inc., a subsidiary of Allergan plc
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholi...
    Medical condition: Liver fibrosis in Subjects with Nonalcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Prematurely Ended) AT (Completed) ES (Prematurely Ended) HU (Completed) GB (GB - no longer in EU/EEA) PL (Completed) SI (Completed) GR (Completed) LV (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-000217-32 Sponsor Protocol Number: VK2809-202 Start Date*: 2021-02-16
    Sponsor Name:VIKING THERAPEUTICS, INC.
    Full Title: VK2809 A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VK2809 ADMINISTERED FOR 52 WEEKS FOLLOWED BY A 4-WEEK OFF-DRUG...
    Medical condition: non-alcoholic steatohepatitis with fibrosis
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    20.0 10019805 - Hepatobiliary disorders 10019668 Hepatic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004143-39 Sponsor Protocol Number: SHIP002 Start Date*: 2016-08-09
    Sponsor Name:Erasmus MC
    Full Title: A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with t...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) BE (Ongoing) DK (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001856-51 Sponsor Protocol Number: 12.007 Start Date*: 2014-08-26
    Sponsor Name:Aleksander Krag
    Full Title: Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease: A randomized placebo controlled clinical trial
    Medical condition: Liver fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10016648 Fibrosis liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-005185-18 Sponsor Protocol Number: HEPA-CRV431-207 Start Date*: 2022-07-27
    Sponsor Name:Hepion Pharmaceuticals, Inc.
    Full Title: ASCEND-NASH: A PHASE 2B, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRV431 IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS AND ADVAN...
    Medical condition: NONALCOHOLIC STEATOHEPATITIS AND ADVANCED LIVER FIBROSIS
    Disease: Version SOC Term Classification Code Term Level
    24.1 100000004871 10086370 NASH with fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-005449-35 Sponsor Protocol Number: PTC124-GD-023-CF Start Date*: 2014-08-26
    Sponsor Name: PTC Therapeutics, Inc.
    Full Title: An Open-Label Safety and Efficacy Study for Patients with Nonsense Mutation Cystic Fibrosis Previously Treated with Ataluren (PTC124®)
    Medical condition: Nonsense Mutation Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) SE (Prematurely Ended) IT (Completed) DE (Completed) ES (Completed) FR (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 18 16:41:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA